Pharmaceutical giant AstraZeneca has signed a three year global licensing deal worth $9 million with enteprise intelligence software firm SAS Institute.
SAS software is already used by AstraZeneca in 24 countries, primarily in the area of clinical research and development (R&D). The new license presents the opportunity for expansion of AstraZeneca's usage of the software both within R&D in areas such as drug portfolio management and in new areas such as strategic performance management as well as in sales and marketing.
"We will use SAS enterprise intelligence in business projects that contribute towards two of our key shareholder value goals of becoming a faster and more efficient organisation and growing through new products," says Johnson Idesoh, Head of Development Information Systems at AstraZeneca.
"The use of SAS gives us the ability to access data from a variety of sources, analyse it and draw conclusions within one environment. On a number of drug projects we have experience of rapidly consolidating information, often from as many as 24 different countries, within a few hours using SAS. We also see opportunities to use technologies like data mining in the rapid identification of promising new medicines.